TFF Pharmaceuticals Inc (TFFP) Stock Fundamental Analysis
NASDAQ:TFFP - Nasdaq - US87241J2033 - Common Stock
We assign a fundamental rating of 3 out of 10 to TFFP. TFFP was compared to 195 industry peers in the Pharmaceuticals industry. While TFFP seems to be doing ok healthwise, there are quite some concerns on its profitability. TFFP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TFFP had negative earnings in the past year.
TFFP had a negative operating cash flow in the past year.
TFFP had negative earnings in each of the past 5 years.
In the past 5 years TFFP always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -261.68%, TFFP is not doing good in the industry: 92.67% of the companies in the same industry are doing better.
TFFP has a worse Return On Equity (-590.38%) than 81.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -261.68% | ||
| ROE | -590.38% | ||
| ROIC | N/A |
ROA(3y)-128.2%
ROA(5y)-111.66%
ROE(3y)-147.01%
ROE(5y)-124.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TFFP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TFFP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TFFP has been reduced compared to 1 year ago.
Compared to 5 years ago, TFFP has less shares outstanding
There is no outstanding debt for TFFP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
TFFP has an Altman-Z score of -34.71. This is a bad value and indicates that TFFP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -34.71, TFFP is doing worse than 91.10% of the companies in the same industry.
There is no outstanding debt for TFFP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -34.71 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
TFFP has a Current Ratio of 0.89. This is a bad value and indicates that TFFP is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of TFFP (0.89) is worse than 89.53% of its industry peers.
TFFP has a Quick Ratio of 0.89. This is a bad value and indicates that TFFP is not financially healthy enough and could expect problems in meeting its short term obligations.
TFFP has a Quick ratio of 0.89. This is amonst the worse of the industry: TFFP underperforms 83.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.46% over the past year.
The Revenue has grown by 25.57% in the past year. This is a very strong growth!
EPS 1Y (TTM)50.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
Revenue 1Y (TTM)25.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-17.71%
3.2 Future
Based on estimates for the next years, TFFP will show a very strong growth in Earnings Per Share. The EPS will grow by 21.17% on average per year.
TFFP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 153.49% yearly.
EPS Next Y65.1%
EPS Next 2Y30.1%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue Next Year60.13%
Revenue Next 2Y5.41%
Revenue Next 3Y153.49%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TFFP. In the last year negative earnings were reported.
Also next year TFFP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TFFP's earnings are expected to grow with 21.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.1%
EPS Next 3Y21.17%
5. Dividend
5.1 Amount
No dividends for TFFP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TFF Pharmaceuticals Inc
NASDAQ:TFFP (12/12/2024, 8:00:00 PM)
After market: 0.135 +0.07 (+107.69%)0.065
-0.1 (-60.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners22.48%
Inst Owner Change-10.13%
Ins Owners3.36%
Ins Owner Change0%
Market Cap288.60K
Analysts82.86
Price Target30.6 (46976.92%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.8%
Min EPS beat(2)1.96%
Max EPS beat(2)29.64%
EPS beat(4)3
Avg EPS beat(4)8.63%
Min EPS beat(4)-4.11%
Max EPS beat(4)29.64%
EPS beat(8)7
Avg EPS beat(8)20.47%
EPS beat(12)9
Avg EPS beat(12)12.21%
EPS beat(16)10
Avg EPS beat(16)4.34%
Revenue beat(2)1
Avg Revenue beat(2)159.82%
Min Revenue beat(2)-5.2%
Max Revenue beat(2)324.84%
Revenue beat(4)3
Avg Revenue beat(4)124.27%
Min Revenue beat(4)-5.2%
Max Revenue beat(4)324.84%
Revenue beat(8)6
Avg Revenue beat(8)325.23%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)22.34%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)166.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.09 | ||
| P/tB | 0.09 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.44
EYN/A
EPS(NY)-3.85
Fwd EYN/A
FCF(TTM)-2.85
FCFYN/A
OCF(TTM)-2.84
OCFYN/A
SpS0.26
BVpS0.71
TBVpS0.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -261.68% | ||
| ROE | -590.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-128.2%
ROA(5y)-111.66%
ROE(3y)-147.01%
ROE(5y)-124.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | -34.71 |
F-Score4
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)402.4%
Cap/Depr(5y)N/A
Cap/Sales(3y)429.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
EPS Next Y65.1%
EPS Next 2Y30.1%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue 1Y (TTM)25.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-17.71%
Revenue Next Year60.13%
Revenue Next 2Y5.41%
Revenue Next 3Y153.49%
Revenue Next 5YN/A
EBIT growth 1Y21.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year209.69%
EBIT Next 3Y45.36%
EBIT Next 5YN/A
FCF growth 1Y60.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.76%
OCF growth 3YN/A
OCF growth 5YN/A